Tolvasca 15 mg (Tolvaptan)

Product Overview

Tolvasca 15 mg is a prescription oral tablet formulated by Glenmark Pharmaceuticals Ltd. The product is marketed for the management of Syndrome of Inappropriate Antidiuretic Hormone Secretion, a condition that leads to water retention and dilutional hyponatremia. Each strip contains four film‑coated tablets and is available in pack sizes of 28, 56, or 84 tablets, allowing patients to select a quantity that matches their treatment duration. The medication is manufactured under Good Manufacturing Practice standards and complies with regulatory requirements in the United States and other markets. The tablets are packaged in a moisture‑resistant foil to preserve potency throughout the shelf life.

What is Tolvasca 15 mg

Tolvasca 15 mg contains the active pharmaceutical ingredient Tolvaptan, which is classified as a selective vasopressin V2 receptor antagonist. The drug is formulated as a tablet strength of 15 milligrams per unit and is identified by the brand name Tolvasca, produced by Glenmark Pharmaceuticals Ltd. Its chemical structure is derived from a class of compounds that block the action of antidiuretic hormone at the V2 receptor in the kidney collecting ducts, thereby reducing water reabsorption. The medication is indicated specifically for the treatment of SIADH and is administered orally.

Uses and Benefits

The primary therapeutic use of Tolvasca is to correct serum sodium concentrations that have fallen below normal levels as a result of SIADH. By promoting the excretion of excess free water, the drug helps restore a healthier electrolyte balance, which can alleviate symptoms such as headache, nausea, confusion, and muscle cramps that are commonly associated with hyponatremia. In clinical practice, patients often report improved mental alertness, better exercise tolerance, and a reduced need for frequent hospital visits when the medication is used as directed. Long‑term treatment may also lower the risk of complications such as seizures or cerebral edema, particularly in pediatric populations.

How It Works

Tolvaptan exerts its pharmacological effect by selectively blocking the V2 subtype of the vasopressin receptor that is normally activated by antidiuretic hormone. This blockade prevents the hormone from stimulating the insertion of aquaporin‑2 water channels into the apical membrane of renal collecting‑duct cells, a process that normally promotes water reabsorption. As a consequence, the kidneys increase urine output while retaining sodium, leading to a net loss of free water and a rise in serum sodium concentration. The onset of diuretic effect is typically observed within a few hours after dosing, and the magnitude of the response is dose‑dependent. Tolvaptan is eliminated primarily through hepatic metabolism by the CYP3A4 enzyme pathway, and its elimination half‑life averages around 8 to 12 hours, supporting once‑daily dosing.

Dosage Guidelines

The recommended initial dosing regimen for Tolvasca 15 mg involves a single tablet taken once daily, preferably under medical supervision to assess tolerability. After the first dose, clinicians may adjust the dose to 30 mg once daily based on serum sodium levels and the patient’s clinical response. Routine laboratory monitoring, including serum sodium, osmolality, and liver function tests, is advised at regular intervals to guide dose titration. In patients with mild to moderate hepatic impairment, a lower maintenance dose may be appropriate, whereas those with severe liver disease should use the medication with caution. Pediatric patients weighing less than 30 kilograms have not been studied sufficiently, and the drug is not currently recommended for use in this age group.

Side Effects

Common adverse reactions observed with Tolvasca include dry mouth, increased thirst, mild nausea, and occasional dizziness. These effects are generally mild to moderate and often diminish with continued therapy. Less frequent but clinically important side effects may involve elevations in liver enzymes, allergic skin reactions such as rash or itching, and symptomatic hypotension. In rare cases, patients may experience severe liver injury or hyponatremia worsening if the drug is discontinued abruptly. Patients are advised to report any persistent gastrointestinal discomfort, unexplained fatigue, or changes in urine output to their healthcare provider promptly.

Warnings and Precautions

Before initiating therapy with Tolvasca, healthcare providers should obtain a complete medical history, focusing on liver disease, electrolyte disturbances, and concurrent medications that may interact with the drug. The medication is contraindicated in individuals with known hypersensitivity to Tolvaptan or any of the inactive ingredients. Concomitant use of strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or clarithromycin can increase plasma concentrations of Tolvaptan, necessitating dose reduction or avoidance. Tolvaptan is classified as a Category C medication in pregnancy, meaning that animal studies have shown adverse effects, and the drug should only be used if the potential benefit justifies the potential risk. Breastfeeding is not recommended while taking Tolvasca, as the drug may be excreted in milk. Patients with severe hepatic impairment should avoid the medication, and dose adjustments are required in those with moderate impairment. Proper storage at room temperature, away from moisture and heat, helps maintain tablet integrity.

Frequently Asked Questions

What condition does Tolvasca treat

Tolvasca is specifically indicated for the treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion, a condition characterized by the abnormal release of antidiuretic hormone (ADH) that leads to water retention and dilutional hyponatremia. In patients with SIADH, the excessive ADH activity causes the kidneys to reabsorb water excessively, resulting in low serum sodium levels. Tolvasca works by blocking the V2 receptor in the kidney, thereby reducing water reabsorption and helping to normalize serum sodium concentrations. This therapeutic effect can alleviate symptoms such as headache, nausea, confusion, and muscle cramps associated with hyponatremia.

How quickly does Tolvasca lower sodium levels

Clinical studies have demonstrated that serum sodium levels often begin to rise within 24 to 48 hours after the first dose of Tolvasca. The magnitude of increase can be modest initially, but with continued daily dosing the improvement becomes more pronounced, reaching a maximum effect after several days of therapy. Factors such as the baseline severity of hyponatremia, the administered dose, and individual patient variability influence the speed of response. Regular laboratory monitoring is recommended to track sodium concentrations and adjust dosing as needed.

Can Tolvasca be taken with other medications

Tolvasca may interact with several classes of drugs, particularly those that are strong inhibitors of the CYP3A4 enzyme, including ketoconazole, itraconazole, clarithromycin, and erythromycin. When these agents are co‑administered, they can increase the plasma concentration of Tolvaptan, potentially raising the risk of adverse effects. Therefore, clinicians may need to adjust the dose of Tolvasca or select alternative therapies when such medications are required. Patients should always inform their prescribing physician about all prescription, over‑the‑counter, and herbal products they are using.

Is long‑term use safe

Extended treatment with Tolvasca has been evaluated in multiple clinical trials involving patients with chronic SIADH. Overall, the medication is generally well tolerated when used according to recommended dosing and monitoring protocols. Ongoing surveillance of liver function and serum electrolytes is advised, as rare cases of hepatic enzyme elevation have been reported. Nevertheless, the safety profile supports the use of Tolvasca for prolonged periods in appropriate patients, provided that regular follow‑up visits are maintained.

Where can I find more information about SIADH

Additional details about the pathophysiology, diagnosis, and management of SIADH are available from reputable medical resources such as the National Institute of Diabetes and Digestive and Kidney Diseases at https://www.niddk.nih.gov and the U.S. Food and Drug Administration at https://www.fda.gov/drugs. These sites provide evidence‑based information on clinical guidelines, patient education materials, and regulatory updates related to the condition and its treatments.

Related Products

• Candid B Cream (Clotrimazole/Beclometasone)
• Candid Cream (Clotrimazole)
• Glinate 60 mg (Nateglinide)
• Mignar 25 mg (Miglitol)
• Natrise 15 mg (Tolvaptan)
• Fenza 2% Cream (Fenticonazole)
• Tazret Forte Cream (Tazarotene)
• Tazret Gel 0.05% (Tazarotene)
• Ifin (Terbinafine)
• Ifin 250 mg (Terbinafine)
• Ifin 500 mg (Terbinafine)
• Tigi 50 mg (Tigecycline)